
TheraCell expanded its licensing agreement with Australian Biotechnologies to include exclusive rights to produce and market a portfolio of demineralized fiber grafts for the Australian and New Zealand markets.
The existing license, addressing TheraCell’s base demineralized fiber technology, now includes a full portfolio of novel TheraFuze DBF® graft forms, including the DBF Fiber Anchorâ„¢ for immediate enhanced screw fixation, DBF Fiber Bulletsâ„¢ for delivery through a cannula in MIS cases, DBF Fiber Wrapâ„¢ and the DBF Fiber Bagâ„¢ for graft containment, and a 3-level DBF Fiber Boatâ„¢.
TheraCell’s Chief Technology Officer, Andy Carter, Ph.D., said, “These unique DBF allografts, particularly the TheraFuze DBF Fiber Anchor, have been received with great enthusiasm by surgeons in the U.S., and we are excited to make them available to our partner, Australian Biotechnologies.”
TheraCell expanded its licensing agreement with Australian Biotechnologies to include exclusive rights to produce and market a portfolio of demineralized fiber grafts for the Australian and New Zealand markets.
The existing license, addressing TheraCell's base demineralized fiber technology, now includes a full portfolio of novel...
TheraCell expanded its licensing agreement with Australian Biotechnologies to include exclusive rights to produce and market a portfolio of demineralized fiber grafts for the Australian and New Zealand markets.
The existing license, addressing TheraCell’s base demineralized fiber technology, now includes a full portfolio of novel TheraFuze DBF® graft forms, including the DBF Fiber Anchorâ„¢ for immediate enhanced screw fixation, DBF Fiber Bulletsâ„¢ for delivery through a cannula in MIS cases, DBF Fiber Wrapâ„¢ and the DBF Fiber Bagâ„¢ for graft containment, and a 3-level DBF Fiber Boatâ„¢.
TheraCell’s Chief Technology Officer, Andy Carter, Ph.D., said, “These unique DBF allografts, particularly the TheraFuze DBF Fiber Anchor, have been received with great enthusiasm by surgeons in the U.S., and we are excited to make them available to our partner, Australian Biotechnologies.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.